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Myelosuppression that occurs during chemotherapy has been reported to be a predictor of better survival in patients with breast or
lung carcinomas. We evaluated the prognostic implications of chemotherapy-induced neutropenia in advanced gastric carcinoma.
Data from a prospective survey of oral fluoropyrimidine S-1 for advanced gastric cancer patients in Japan were reviewed. We
identified 1055 untreated patients with adequate baseline bone marrow function. During treatment with S-1, a total of 293 (28%)
patients experienced grade 1 or higher neutropenia. The adjusted hazard ratio of death for the presence of neutropenia, as
compared with the absence of such toxicity, from a multivariate Cox model was 0.72 (95% confidence interval, 0.54–0.95;
P¼0.0189) for grade 1 neutropenia, 0.63 (0.50–0.78; Po0.0001) for grade 2 neutropenia and 0.71 (0.51–0.98; P¼0.0388) for
grade 3–4 neutropenia. These findings suggest that the occurrence of neutropenia during chemotherapy is an independent predictor
of increased survival in patients with advanced gastric cancer, whereas the absence of such toxicity indicates that the dosages of drugs
are not pharmacologically adequate. Monitoring of neutropenia in patients who receive chemotherapy may contribute to improved
drug efficacy and favourable survival.
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The dose intensity is recognised as a key element in a patient’s
response to cytotoxic drugs. In general, it is considered that the
higher the dose intensity, the greater the chance that the optimal
dose is approached (Frei and Canellos, 1980). Neutropenia is one
of the most important dose-limiting toxicities of cytotoxic drugs,
often necessitating a reduction from the initial dosage (Crawford
et al, 2004). Therefore, many oncologists may consider that the
absence of haematological toxicity will raise the hope of an
adequate tumour response without myelosuppression. Since the
late 1990s, however, several studies have reported that neutropenia
or leucopenia occurring during chemotherapy is a sign of patient’s
response to adjuvant chemotherapy in women with breast cancer;
a significantly longer survival results in patients who have those
haematological toxic effects (Saarto et al, 1997; Poikonen et al,
1999; Mayers et al, 2001; Cameron et al, 2003). A recent study by
Di Maio et al (2005) confirmed the positive correlation between
chemotherapy-induced neutropenia and increased survival in a
pooled analysis of three randomised trials that included a total of
1265 patients with advanced non-small-cell lung cancer (NSCLC).
Consideration of these findings led us to review data from a
prospective survey of Japanese patients with advanced gastric
cancer, and to investigate the association between neutropenia
occurring during chemotherapy and patient survival. Our goal was
to provide the initial evidence, through a rigorous statistical
analysis, in a large series of subjects with advanced gastric cancer
as to the utility of neutrophil count as a surrogate indicator of drug
efficacy.
MATERIALS AND METHODS
Patients
The subjects of this study were identified from among the patients
participating in a nationwide survey of oral fluoropyrimidine
derivative S-1 (TS-1
s; Taiho Pharmaceutical Co. Ltd, Tokyo,
Japan) in Japan (Shirasaka et al, 1996). This survey was
prospectively conducted by the manufacturer to obtain safety
data of the drug, and all patients in Japan scheduled for S-1
administration were centrally registered from March 1999 through
March 2000. The protocol of this survey was approved by all
participating centres, and informed consent was obtained from all
the patients prior to participation in this study.
A total of 3758 patients with advanced gastric cancer were
enrolled at more than 700 centres. We identified 1055 subjects who
met the following criteria: age less than 80 years, Eastern
Cooperative Oncology Group (ECOG) performance status (PS) of
0 or 1, sufficient bone marrow function (neutrophils X2.0 10
9l
 1,
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sleucocytes X4.0 and p12.0 10
9l
 1, platelets X100 10
9l
 1 and
haemoglobin X9.5gdl
 1) and no history of chemotherapy within
6 months before the commencement of S-1 treatment. The patients
were followed up until March 2002 to obtain survival information.
Treatment delivery
S-1 was to be taken twice a day orally after meals. The initial dose
was assigned based on the body surface area (BSA) as follows: BSA
o1.25m
2, 40mg (80mgday
 1); BSA X1.25 and o1.50m
2,5 0m g
(100mgday
 1); BSA X1.50m
2, 60mg (120mgday
 1). A single
therapy cycle consisted of S-1 monotherapy for 28 consecutive
days, followed by 14 days of no treatment. This schedule was
repeated every 6 weeks unless the disease progressed or
unacceptable adverse effects occurred. The dose modification
scheme followed that in the previous trials of S-1 (Sakata et al,
1998; Koizumi et al, 2000); when haematological adverse reactions
at grade 3–4 or non-haematological reactions at grade 2–4
appeared, the dose was reduced from 120 to 100mgday
 1 and
from 100 to 80mgday
 1, respectively, or administration was
temporarily discontinued.
The dose intensity was calculated as the total dose administered
divided by the duration of time over which it was given. The
relative dose intensity (RDI) was then calculated as the ratio of the
actual dose intensity to the ideal value if planned doses were all
given on schedule (Hryniuk and Levine, 1986).
Study endpoint and assessment of haematological toxicity
The study endpoint was overall survival. This was defined as the
interval between the date of the beginning of S-1 treatment and the
date of death or last follow-up. Haematological toxicity, including
neutropenia, leucopenia, thrombocytopenia and decreased haemo-
globin level, was graded according to the National Cancer
Institute Common Terminology Criteria for Adverse Events
(NCI-CTCAE), version 3. The central data centre conducted onsite
monitoring weekly during the first cycle and biweekly during and
after the second cycle in order to confirm results of laboratory
tests. The data centre collected and managed all the data regarding
blood cell counts and grades of haematological toxicity.
Statistical methods
In order to evaluate the prognostic implications of chemotherapy-
induced neutropenia, we first identified the worst grade of
neutropenia during treatment with S-1 for each patient. Owing
to the size of the study group, we classified neutropenia into four
categories: absent (grade 0), mild (grade 1), moderate (grade 2)
and severe (grade 3–4). The survival curves of the four categories
were estimated by the Kaplan–Meier method and compared by the
log-rank test. This approach, considering the occurrence of
myelosuppression during chemotherapy to be a baseline feature,
has been used in many studies (Saarto et al, 1997; Poikonen et al,
1999; Cameron et al, 2003; Nakata et al, 2006) and is appropriate in
an adjuvant setting, as the number of patients who die during the
chemotherapy treatment period is usually negligible. In advanced
cancer, however, considering myelosuppression to be a baseline
feature can lead to a large bias because fewer cycles of chemo-
therapy can be administered due to poorer outcomes, conse-
quently leading to a lower chance of neutropenia. In other words,
patients who have better outcomes can receive many cycles of
treatment, thus resulting in a higher incidence of chemotherapy-
induced neutropenia. This can produce a false-positive association
between chemotherapy-induced neutropenia and increased
survival. To avoid this problem, a landmark analysis is sometimes
employed, in which the study is limited to patients who survive for
at least certain specific time period after the initiation of treatment,
with neutropenia during that period considered as a baseline
feature (Di Maio et al, 2005). However, such a landmark analysis
would discard information regarding deaths occurring ‘before the
landmark’, which could bias patient selection (Green et al, 2002).
Further, our protocol required that treatment with S-1 would
continue until the occurrence of disease progression or unaccep-
table toxicity. Consequently, a certain number of patients
continued the treatment for prolonged period and experienced
the late onset of neutropenia. A landmark analysis would easily be
biased by neutropenia occurring ‘after the landmark’, and thus be
unsuitable for our study. Instead, we treated chemotherapy-
induced neutropenia as a time-dependent variable; for each
patient, the worst grade of neutropenia occurring between the
beginning of S-1 treatment and time T40 was defined as the value
of the variable at T. The variable value for each patient could
change over time according to the worst grade of neutropenia
experienced by that time. To quantify the impact of time-
dependent neutropenia on survival, a Cox regression model was
used to estimate the hazard ratio (HR) of death (Hosmer and
Lemeshow, 1999). We also considered a multivariate Cox model
that included other clinical features to obtain an adjusted HR and
to examine the independent prognostic role of chemotherapy-
induced neutropenia. A method by Simon and Makuch (1984) was
used for a graphical representation of the survival curves
according to the worst grade of neutropenia, which was considered
to be a time-dependent variable; this method accounted for
patients transferring from one group to another. All reported P
values of statistical tests are two-tailed and Po0.05 was taken to be
statistically significant. All analyses were performed using SAS
(version 9.13) or S-PLUS (version 6.2).
RESULTS
Incidence of neutropenia
Table 1 shows the worst grade of neutropenia according to the
treatment cycle of chemotherapy in the study subjects (n¼1055).
Cumulatively, a total of 637 cases of neutropenia (grades 1–4) were
reported; among these, 206 cases were grade 1, 328 cases were grade
2, 91 cases were grade 3 and 12 cases were grade 4 (Table 1). The
study protocol did not allow the prophylactic use of granulocyte-
colony-stimulating factor (G-CSF), and no such use was reported.
The results were therefore not biased regarding the use of G-CSF.
Survival data according to the worst grade of neutropenia
The demographics and clinical/haematological characteristics of
the study population are summarised in the leftmost column of
Table 2. On the whole, patient demographics such as age, gender or
BSA were very similar to those observed in the previous trials
of S-1 (Sakata et al, 1998; Koizumi et al, 2000). The median values
Table 1 Worst grade of neutropenia according to the treatment cycle of
chemotherapy
Treatment
cycle
a 1 2345678 9 – 1 5
b
No. of
patients 1055 813 520 398 296 224 169 132 104 Total
Grade 1 63 44 31 25 17 5 5 6 10 206
Grade 2 108 66 48 39 21 15 8 7 16 328
Grade 3 31 22 12 10 4 4 4 3 1 91
Grade 4 6 3 1 1 1 12
Grade 1–4 208 135 92 75 42 24 17 17 27 637
aSingle cycle consisted of 42 days (S-1 therapy for 28 consecutive days followed by 14
days of no treatment).
bNeutropenia was observed until the 15th cycle.
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sof the baseline leucocyte count and of the baseline neutrophil count
were 6.3 10
9l
 1 (range, 4.0–12.0) and 4.0 10
9l
 1 (range, 2.0–
10.9), respectively. The median RDI was 0.86 (range, 0.11–1.24),
indicating that compliance for S-1 treatment was good overall.
There were 293 patients (28% out of the 1055 patients) who
experienced neutropenia; among whom, 73 patients (7%) had
grade 1 as the worst grade, 156 patients (15%) had grade 2 and 64
patients (6%) had grade 3 or higher. Of these patients with
neutropenia, the worst grade initially occurred during the first
cycle in 177 patients, during the second cycle in 57 patients, during
the third cycle in 21 patients, during the fourth cycle in 19 patients,
during the fifth cycle in patients and during the sixth or
subsequent cycles in 11 patients. The characteristics of the
patients, according to the worst grade of neutropenia experienced,
are shown in Table 2. The dose intensity was lower in the patients
with severe neutropenia; the median RDI in the patients with grade
3–4 neutropenia was 0.79 (range, 0.32–1.07), whereas that was
0.86 (range, 0.11–1.24) in the patients with no neutropenia
(Table 2).
We compared the survival curves for subgroups of patients
identified by the worst grade of neutropenia. As stated above, this
simple approach may be subject to potential bias, but nevertheless
it can be informative for a preliminary analysis. Figure 1 shows the
survival curves (A) for all the patients and (B) for subgroups of
patients stratified according to the worst grade of neutropenia. A
total of 795 deaths (75%) were confirmed, including 767 deaths
that were reported as tumour-related. The median follow-up of the
260 surviving patients was 472 days (range, 9–1136 days). The
median survival of all the patients was 302 days (95% confidence
interval (CI), 270–318 days) with 1- and 2-year survival rates of
40% (95% CI, 37–43%) and 18% (95% CI, 16–21%), respectively
(Figure 1A). According to the severity of neutropenia, the median
survival was 254 days (95% CI, 239–281 days) for patients with no
neutropenia (grade 0), 355 days (95% CI, 309–415 days) for
patients with mild neutropenia (grade 1), 459 days (95% CI, 377–
559 days) for patients with moderate neutropenia (grade 2) and
480 days (95% CI, 380–552 days) for patients with severe
neutropenia (grade 3–4) (Figure 1B). The log-rank test showed
that the differences among the four curves were statistically
significant (Po0.0001).
Association of survival with the time-dependent
neutropenia variable
Table 3 shows the result of a Cox regression analysis for the
association between overall survival and the worst grade of
neutropenia, which was treated as a time-dependent variable. The
HR for mild (grade 1) neutropenia in comparison with no
neutropenia (grade 0) was 0.74 (95% CI, 0.56–0.98; P¼0.0330),
which translated into a 26% lower risk of death. Similarly, the HR
for moderate (grade 2) neutropenia in comparison with no
neutropenia was 0.55 (95% CI, 0.44–0.68; Po0.0001), which
represented a 45% lower risk of death, and the HR for severe
(grade 3–4) neutropenia in comparison with no neutropenia was
0.62 (95% CI, 0.44–0.85; P¼0.0037), which was a 38% lower risk
of death. Figure 2 shows the graphical representation of survival
Table 2 Baseline demographics and clinical/haematological characteristics in all patients and in subgroups stratified according to the worst grade of
neutropenia
All patients (n¼1055) Grade 0 (n¼762) Grade 1 (n¼73) Grade 2 (n¼156) Grade 3–4 (n¼64)
Age, median (range) 63 (23–80) 63 (23–80) 63 (28–78) 63 (34–80) 60 (26–80)
Gender, male/female (%) 768/287 (73/27) 574/188 (75/25) 48/25 (66/34) 105/51 (67/33) 41/23 (64/36)
BSA, median (range) 1.48 (1.04–2.01) 1.49 (1.11–2.01) 1.46 (1.04–1.88) 1.46 (1.08–1.87) 1.46 (1.10–1.74)
ECOG PS, 0/1 (%) 681/374 (65/35) 487/275 (64/36) 45/28 (62/38) 106/50 (68/32) 43/21 (67/33)
Disease status, recurrent/advanced (%) 341/714 (32/68) 244/518 (32/68) 21/52 (29/71) 46/110 (29/71) 30/34 (47/53)
Liver metastasis, absent/present (%) 775/280 (73/27) 530/232 (70/30) 56/232 (77/23) 134/22 (87/13) 55/9 (86/14)
Leucocytes, median (range) 6.3 (4.0–12.0) 6.6 (4.0–12.0) 6.0 (4.3–11.3) 5.5 (4.0–11.5) 5.6 (4.0–9.6)
Neutrophils, median (range) 4.0 (2.0–10.9) 4.3 (2.0–10.9) 3.9 (2.0–7.3) 3.4 (2.2–8.1) 3.3 (2.1–7.6)
Treatment cycles, median (range) 2 (1–20) 2 (1–18) 4 (1–14) 4 (1–20) 3 (1–16)
Treatment duration, median (range) 108 (2–889) 86 (2–889) 162 (28–609) 181 (7–794) 144 (3–754)
RDI, median (range) 0.86 (0.11–1.24) 0.86 (0.11–1.24) 0.85 (0.22–1.11) 0.85 (0.39–1.20) 0.79 (0.32–1.07)
Abbreviations: BSA, body surface area; ECOG PS, Eastern Cooperative Oncology Group performance status. Units: age (years), BSA (m
2), leucocytes ( 10
9l
 1), neutrophils
( 10
9l
 1), treatment duration (days).
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Figure 1 (A) Kaplan–Meier survival curve for all 1055 patients. (B)
Kaplan–Meier survival curves according to the worst grade of chemo-
therapy-induced neutropenia. The log-rank test showed that the differ-
ences among the four curves were statistically significant (Po0.0001).
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scurves according to the worst grade of neutropenia in a time-
dependent manner, allowing patients to be transferred from one
group to another (Simon and Makuch, 1984; Richardson et al,
2003).
A multivariate Cox regression model including other clinical
features (age, gender, BSA, ECOG PS, disease status, liver
metastasis and leucocyte count) also demonstrated that any grade
of neutropenia was independently associated with a better survival
(Table 4). The adjusted HRs for mild, moderate and severe
neutropenia in comparison with no neutropenia were 0.72 (95%
CI, 0.54–0.95; P¼0.0189), 0.63 (95% CI, 0.50–0.78; Po0.0001)
and 0.71 (95% CI, 0.51–0.98; P¼0.0388), respectively. Therefore,
patients who experienced neutropenia had a more favourable
prognosis, and the presence of moderate neutropenia suggested a
higher efficacy of the drug than did the presence of either mild
neutropenia or no neutropenia.
It is notable that patients with a leucocyte count X9.0 10
9l
 1
had a significantly poorer survival when compared with those with
a leucocyte count o9.0 10
9l
 1 (HR¼1.46; 95% CI, 1.19–1.80;
P¼0.0004; Table 4). Several recent studies have reported that large
numbers of leucocytes and their cytokine production correlate well
with tumour development and severity (Coussens and Werb, 2002;
Balkwill, 2004). It is also often clinically observed in advanced
cancer that the neutrophil count elevates in accordance with an
increased number of leucocytes. This implies that there is a
potential link between a high density of neutrophils and a poor
prognosis, thus leading to a false association between patients
experiencing no neutropenia during chemotherapy and unfavour-
able survival outcomes. However, the multivariate analysis,
adjusted by the leucocyte count, did not affect the significant
association between neutropenia and survival, implying that
neutropenia is independently predictive of the prognosis (Table 4).
We can observe that there was a trend for BSA being predictive
of overall survival (HR¼0.87; 95% CI¼0.74–1.02; P¼0.0878),
although the statistical test did not reach a 5% significance
(Table 4). This in turn suggested that higher dose might be related
to better outcome in our dose-banding approach for S-1. However,
BSA, which is defined by height and weight, showed a very high
correlation with weight (Pearson correlation coefficient¼0.962,
Po0.0001) and it was thus likely that the above trend simply
reflected the fact that patients maintaining weight tended to
survive longer than those losing it. Hence, weight, which can be
reasonably associated with patient’s general condition, could be a
confounding factor in this case.
Finally, we performed similar analysis for other haematological
manifestations of toxicity, including leucopenia, haemoglobin
decrease and thrombocytopenia. However, none of these variables
remained as significant factors in the multivariate model (data not
shown).
DISCUSSION
The objective of this study was to investigate whether chemo-
therapy-induced neutropenia was related to increased survival
and could therefore be used as a surrogate indicator of patient
prognosis. Since the late 1990s, several studies have linked
myelosuppression induced by adjuvant chemotherapy to a better
outcome in patients with breast cancer (Saarto et al, 1997;
Poikonen et al, 1999; Mayers et al, 2001; Cameron et al, 2003).
Recently, Di Maio et al (2005) reported the first evidence regarding
the relationship between chemotherapy-induced neutropenia and
longer survival time in patients with an advanced stage of cancer.
They analysed the pooled data from three randomised trials of
1265 patients with advanced NSCLC treated with one of five
different regimens, and concluded that both mild (grade 1–2) and
severe (grade 3–4) neutropenia similarly predicted longer patient
survival than did the absence of such toxicity. Nakata et al (2006)
Table 3 Cox model for the association between survival and chemo-
therapy-induced neutropenia
a
Neutropenia Hazard ratio (95% CI) P
Grade 0 1.00 (referent)
Grade 1 0.74 (0.56–0.98) 0.0330
Grade 2 0.55 (0.44–0.68) o0.0001
Grade 3–4 0.62 (0.44–0.85) 0.0037
aNeutropenia is treated as a time-dependent variable.
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Figure 2 Survival curves as a function of chemotherapy-induced
neutropenia treated in a time-dependent manner, by the method of
Simon and Makuch with the landmark time of 14 days.
Table 4 Multivariate Cox model for the association between survival
and chemotherapy-induced neutropenia
a
Adjusted hazard ratio (95% CI) P
Neutropenia
1 vs 0 0.72 (0.54–0.95) 0.0189
2 vs 0 0.63 (0.50–0.78) o0.0001
3–4 vs 0 0.71 (0.51–0.98) 0.0388
Age
X60 vs o60 0.97 (0.84–1.13) 0.7012
Gender
Male vs female 1.12 (0.94–1.34) 0.2167
BSA (m
2)
X1.50 vs o1.50 0.87 (0.74–1.02) 0.0878
ECOG PS
1 vs 0 1.48 (1.28–1.71) o0.0001
Disease status
Advanced vs recurrent 1.20 (1.03–1.40) 0.0199
Liver metastasis
Present vs absent 1.73 (1.47–2.03) o0.0001
Leucocytes ( 10
9l
 1)
9.0–12.0 vs 4.0–9.0 1.46 (1.19–1.80) 0.0004
Abbreviations: BSA, body surface area; ECOG PS, Eastern Cooperative Oncology
Group performance.
aNeutropenia is treated as a time-dependent variable.
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sexamined the prognostic role of neutropenia in a phase I study
of 23 patients with advanced gastric cancer receiving S-1 plus
cisplatin. These findings prompted us to perform a rigorous
quantification of the prognostic value of chemotherapy-induced
neutropenia with respect to survival outcomes in patients with
advanced gastric cancer. In comparison with previous investiga-
tions, an advantage of our study is that a large number of patients
received the same treatment with S-1 monotherapy according to
the schedule used in previous clinical trials. Further, the survey
entailed central data collection and management and frequent site-
visit monitoring in order to ensure data quality.
In our study, the association between patients experiencing
neutropenia and survival prolongation was considerable. The
patients with a grade 1 or greater decrease in their neutrophil
count had significantly better survival outcomes than did patients
without such toxicity, indicating that chemotherapy-induced
neutropenia may provide an index of delivering an optimal dose
of chemotherapy that is required for generating an active
antitumour effect. Moreover, the median RDI of S-1 in patients
with neutropenia was less than that in patients with no
neutropenia (Table 2). These results lead us to recognise the
possibility that optimal dosing is not necessarily governed by the
use of BSA-dosing guidelines; in fact, a poor correlation between
BSA and the pharmacokinetics of most cytotoxic agents has been
critically pointed out (Gurney, 1996, 2002; Ratain, 1998; Newell,
2002). Several prospective randomised studies have investigated
the dose–response relationship in breast carcinoma (Fumoleau
et al, 1993; Wood et al, 1994; Fisher et al, 1997) in order to assess
the preference for higher doses than those guided by the BSA
criteria. If, however, the BSA-based dosing system is not
appropriate, then the optimal dose of chemotherapy for individual
patients is relatively unrelated to whether the dose is high or low in
terms of the BSA-based one.
When oncologists conduct phase II or III clinical trials, they
predefine a schedule for dose reduction in the event of
myelosuppression. In contrast, the dose is not increased in the
absence of such toxicity. Similar guidelines are usually followed in
daily clinical practice. This apparent asymmetry results from the
presumption that the doses directed by BSA are valid for most, if
not all, patients and that patients without toxicity such as
myelosuppression will continue to derive substantial benefits from
treatment. However, our study and that of others suggest that the
absence of neutropenia may actually be a sign of an inadequate
dose of chemotherapy (Kvinnsland, 1999). If this is the case, then
the fact that more than 70% of patients in our study did not
experience neutropenia in their treatment implies that the
traditional BSA-based dose is far from optimal in ensuring that
the majority of patients receive an effective dose.
Our analysis demonstrated that the patients with neutropenia
had a significantly better survival than did the patients without
neutropenia, and that severe (grade 3–4) neutropenia did not
indicate a better survival than mild (grade 1) or moderate (grade 2)
neutropenia. This result is precisely consistent with that obtained
for the chemotherapy of NSCLC (Di Maio et al, 2005). In addition,
our rigorous statistical approach elucidated that patients with
moderate neutropenia reaped greater survival benefits from the
treatment than did the patients with mild neutropenia. These
findings provide us with a possible approach for fine-tuning of the
initial dose of S-1, which is selected according to BSA; unless other
severe toxicities are observed, a dose level that decreases the
neutrophil count to 1.0–1.5 10
9l
 1 (grade 2) is required for
active antitumour effects. This approach would be most beneficial
early on in treatment. Indeed, there were 884 (84% of the study
population) patients who remained at grade 0–1 neutropenia in
the first and second cycles of treatment. Of these, 428 (41%)
patients experienced neither moderate/severe haematological
toxicity (grade 2–4 leucopenia, haemoglobin decrease or thrombo-
cytopenia) nor any grade of key non-haematological toxicity
(grade 1–4 nausea, vomiting, diarrhoea, stomatitis, dermatosis)
in the first and second cycles. An early dose increase aimed
at moderate neutropenia could have been conducted safely for
these patients and thus a significant number of patients were
expected to fall under this category and receive more survival
benefit from S-1.
On the other hand, a dose increase based on lack of neutropenia
in the first and second cycles would clearly be a problem for
patients exhibiting severe toxicity later on in treatment. In this
sense, an early dose modification does not allow for the
development of late toxicity. However, the number of patients
who remained at grade 0–1 neutropenia in the first and second
cycles but thereafter developed neutropenia or one of the above
eight toxicities to a grade 3–4 level was only 54. Thus, an early
dose increase would not be a problem for most of the patients
targeted in our approach.
In our study, the prognostic impact of neutropenia as a marker
for delivering the optimal dose was estimated to be 0.6–0.7 in
terms of HR, similar to the survival benefit reported in the NSCLC
study (Di Maio et al, 2005). This improvement in outcome would
be equivalent to, if not greater than, that generally expected for
chemotherapeutic regimens in experimental arms of phase III
studies. Thus, the use of chemotherapy-induced neutropenia may
prompt the more rational use of available drugs and benefit a large
proportion of patients who are currently receiving unintentional
under-dosing of cytotoxic chemotherapy. Although it remains
unclear why the plateau of dose–response appears in proximity to
the dose that produces modest neutropenia, accumulating
evidence indicates that the possibility of using toxicity as a guide
for tailored dosages deserves more attention for both curable and
non-curable treatments.
In conclusion, we confirmed the prognostic implications of
chemotherapy-induced neutropenia through the analysis of a large
series of advanced gastric cancer patients treated with S-1. Our
study suggests that chemotherapy-induced neutropenia can be
used to individualise a pharmacologically active dose. Prospective
randomised trials to explore safe intrapatient dose escalation with
the intent of achieving neutropenia are thus warranted.
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